Form 4: Mineralys Therapeutics CEO Jon Congleton Sells Shares Under 10b5-1 Trading Plan

Mineralys Therapeutics CEO Jon Congleton sold 15,271 shares of common stock at a weighted average price of $13.518 per share on October 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 11, 2024, Jon Congleton, the CEO of Mineralys Therapeutics, sold 15,271 shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on January 30, 2024.
• The shares were sold at prices ranging from $13.35 to $13.76, with a weighted average price of $13.518.
• Following the transaction, Congleton directly owns 895,941 shares of Mineralys Therapeutics.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission (SEC) on October 15, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports a stock sale by the CEO under a pre-arranged trading plan, which is a common and legal practice. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically views these sales in the context of the overall health and prospects of the company.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates